The American Society of Clinical Oncology released an ethical framework for incorporating research biopsies in cancer clinical trials.
The “Data at the Point of Care” pilot program offered by the Centers for Medicare & Medicaid Services will allow participating providers to fill in information gaps through access to structured and complete claims data.
Biosimilars to bevacizumab and trastuzumab are the first biosimilar products to have reached the US market.
New tools are needed to help match patients to investigational therapies and to support physician decision-making. PRECISE represents a novel platform method for successfully matching patients with cancer to molecularly selected studies.
Molecular profiling is able to identify known genomic and methylation alterations of different ovarian cancer subtypes, thus deeming such profiling useful in routine clinical practice, according to a recent study.
The combination of ibrutinib plus venetoclax is well tolerated in patients with relapsed or refractory CLL and provides improved PFS and OS rates, according to recent research.
Ibrutinib plus rituximab provides superior PFS and OS compared with standard chemoimmunotherapy among patients aged 70 years or younger with previously untreated CLL and without an IGHV mutation, according to the results of a new study.
Older patients with cancer living farther from treatment sites may experience more limited access to care; as a result, health care spending could increase for these patients as well as for Medicare, according to new research.